Abstract 2043P
Background
Elderly patients are a heterogeneous group, ranging from fit to frail, with varying disease burden, comorbidities and ability to tolerate cancer-directed treatment. Defining treatment strategies in octogenarians with colorectal cancer (CRC) is challenging due to the high risk of complications and the likelihood of death from other causes. The aim of this study was to evaluate whether CCI and CFS can predict survival in octogenarians with CRC.
Methods
Patients aged 80 and over with CRC, seen at the Multidisciplinary tumor board at our center between January 2020 and December 2022 were evaluated in this study. CCI and CFS were calculated in all patients. Kaplan-Meier method was used to estimate the probability of 1-, 3- and 5-year survival rates (OS) regardless of treatment, and to compare OS estimates based on subjects’ characteristics, CCI and CFS scores.
Results
We analysed 149 patients, median age 82 (range 80-91), with 53% of patients with stage IV CRC. Death was confirmed in 65 patients (44%) during follow-up. Following CFS scoring, patients were classified as frail (44%), pre-frail (45%) and robust (9%). The univariate 1-, 3- and 5-year survival rate estimates in frail group were 89%, 56% and 29%, and in robust/pre-frail group 92%, 85% and 64%. Median OS estimate in frail group was 13.24 months (5.35-21.13), and in robust/pre-frail 113.02 months (56.41-169.63), which was statistically significant, p<0.01. According to CCI scale patients were divided in groups that scored 1-5 (13%), 6-7 (28%), 8-10 (31%) and more than 10 points (24%). In these CCI groups, median OS estimates were as follows: 59.5, NR, 40.4 and 8.28 months, respectively, which proved to be statistically significant (p<0.019). A binomial logistic regression was performed to ascertain the effects of ECOG performance status (PS), CFS and CCI on the likelihood that participants will survive 12 months. Of these three predictor variables, only PS was statistically significant in predicting 1-year survival in this model.
Conclusions
Geriatric assessments (CFS and CCI) were efficient in predicting survival in octogenarians with CRC, with potential implications for shaping the decision-making process for different treatment modalities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06